Early outcomes of Tricuspid Valve Replacement in Patients with Tricuspid Regurgitation: the TRISOL Early Feasibility Study
from EuroIntervention | Editor's Choice
21m 21s
The Trisol TTVR early feasibility study presents promising early results for treating severe tricuspid regurgitation in patients previously excluded from prior therapies. In a single-arm, multicenter trial of 19 patients, the device demonstrated high procedural and clinical success—95% technical success and 100% procedural success—alongside significant improvements in tricuspid regurgitation grade (94% showed ≥2-grade reduction), functional status (improved NYHA class, 6-minute walk test, and KCCQ scores), and right ventricular function. Notably, the study reported no major adverse events such as death, stroke, or myocardial infarction, and only one pacemaker insertion, indicating minimal conduction-related complications. The valve’s large opening (over 5 mm²), low gradient (1.1 to 1.9), and unique bi-leaflet design with continuous blood washout help preserve right ventricular function, a key advantage over existing valves where RV dysfunction commonly worsens. No leaflet thrombosis was observed, addressing a major clinical concern in current tricuspid replacement therapies. The device is retrievable, allows flexible positioning, and can be delivered via neck or groin access. Future pivotal trials will compare Trisol to the Edwards Evolve valve and include patients with challenging anatomy or poor right ventricular function. The results suggest Trisol may offer a safer, more effective, and broadly applicable option for severe tricuspid regurgitation, particularly in high-risk populations.
Welcome to Editors' Choice, the podcast of Euro Intervention, where we highlight the
latest science and research in interventional cardiology.
I'm your host, Aisha Haver, and through conversations with the authors, we explore study design,
key findings, and their relevance in contemporary practice.
In this episode, I'm joined by Professor Isaac George from New York Presbyterian Hospital
Columbia University Irving Medical Center in New York.
And the paper we're discussing is on early outcomes of tricuspid valve replacement in patients
with tricuspid regurgitation, the tri-zoil early feasibility study.
Welcome to the podcast, Professor George.
Thank you so much, Dr. Carter.
It's a pleasure to be here, and I just want to thank the journal and the staff and your
intervention for the opportunity to discuss our paper today, and it's a really exciting
time for the field and for tricel in general.
The tricuspid valve is clearly no longer forgotten about this, an increasing focus on treating
severe TR, so could you provide some background to the current landscape of percutaneous tricuspid
valve treatment strategies?
Absolutely.
You know, here in the United States, we have some differences from the rest of the world.
You guys do have a lot of opportunity for newer devices that maybe see Mark that we
have not been able to use or only use in trial.
Currently, right now in the United States, we have two tricuspid therapies that are commercially
approved.
One is tricuspid edge-to-edge replacement with a tri-clip, the Abbott tri-clip device.
The other is a commercial replacement device from the Edwards evoke replacement system.
Those are available now for patients that are suitable for treatment who have symptomatic
severe tricuspid regurgitation and appropriate anatomy and are deemed to be at elevated
risk or heart surgery.
That approval was in, you know, within the last year or so.
Those pivotal trials were completed and published in the New England Journal of Medicine.
That's really opened up a lot of patients who are otherwise treated with medical therapy
with suboptimal outcomes.
And now we're seeing them in clinics at an increased pace in frequency.
Some of these patients can be treated, some of them can't.
In trials, we have a number of different other repair devices and replacement devices.
And so we're enrolling in these therapies.
We're trying to accumulate data, we're trying to figure out which patients are best for
all of these devices and which fits best for each patient clinically.
In addition, we're also very cognizant that medical therapy plays a very important role
in the treatment for tricuspid regurgitation and getting optimal outcomes for these valve
therapies.
Tell us now how this trisol TTVR system fit into this landscape.
In this early feasibility study, which is a single arm perspective multi-center study,
walk us through the study design, patient eligibility criteria, please.
So this valve is a new valve.
This valve has been around, it's been designed and redesigned, and it's now on its second
to slash third generation.
In this trial, the second generation valve was used.
It has 12 anchors that come out from a housing, capture the leaflets, and then has an
atrial skirt that then gets released.
The valve itself is designed as a very large opening valve.
It has two leaflets that are bovine pericardium.
These leaflets function in a bi-leaflet fashion in a very unique way.
It's very interesting to see how these leaflets work, and they have some very unique properties.
They opening and closing forces are overall low, and they provide washing throughout the
entire cycle.
There's a very small amount of washing backwards during closure, but we actually feel that
that's advantageous in two aspects in terms of preservation of RV function, as well as
prevention of leaflet thrombosis, which has become a huge problem in the field.
Do we need more devices?
You know, ultimately yes, I think we have one commercially available replacement device.
We have one edge-to-edge device, but we see a lot of patients that don't fit into either
one of these, or are challenging for any number of reasons.
Technical considerations, imaging can be hard.
They're set to leaflet as inadequate.
They don't fit the dimensions for sizing.
So I think we're seeing that the more devices that we have the better, and ultimately we're
going to need a number of devices to help treat all of these different pathologies and
anatomies, the trisol valve helps us extend that patient portfolio.
It has a sizing that goes up to 65 millimeters, which at the time was the largest annular
size that we could treat out there for any valve, and it's on the largest end.
There's only one other valve that makes a larger size, so that size is extremely large and
is able to treat patients who are late-stage presenters.
The access can be through both the internal jugular vein as well as the groin now, and
so that's an advantage to some devices where you only have either groin access or you only
had IJ access, but we have both, and I think that ultimately as we go down the line, we'll
open up treatment for patients.
There are patients that were excluded from prior trials, both from tier as well as replacement
for either being too sick, RV function to poor conduction problems.
There are a number of different reasons why they were excluded, and we're really looking
to take care of those patients with the trisol valve.
We do think that there are some advantages with RV preservation and RV function preservation,
and we have not been shy about taking care of those patients with trisol, and we have some
preliminary data that is suggestive that this valve works very well at those patients.
In addition, we've had a very low pacemaker rate out of our experience.
We've only had one now out of 20-some patients, and so I think that's a huge advantage trying
to deal with conduction issues on the right side with the tricuspid valve in place, or let's
say, clips or a tier device in place can be really challenging.
I think there are a lot of different reasons that a new valve, which has some new features,
is going to be attractive for patients, where in the midst of an ongoing EFS, the report
shows us the results of the first 19 patients that we've performed, and we have some additional
patients that have been performed, and we're very excited about these results in comparison
to what's on the market right now.
This early feasibility study was a single arm perspective multi-center study.
Could you walk us through the study design and what sort of patients did you recruit?
So, this was a single arm study.
Patients had to be at least 18 years old.
They had to be medically optimized with severe TR with symptoms.
They had to be suitable for a valve implantation with a trisol device.
Additionally, they had to not have severe pulmonary hypertension.
They had to have no prior history of tricuspid valve surgery, an ejection fraction greater
than 25 percent, and in general, comorbidities that would allow them to live more than a year.
In terms of other requirements, they had to be reviewed and seen by a heart failure specialist
to ensure optimal heart failure regimens prior to implantation.
All of the studies, including Echo and CT, were reviewed by a Core Lab.
Calls were then performed to allow patients to be approved with the screening committee,
and then patients were then passed through the process for acceptance into the trial.
Patients are being followed for 30 days and then up to potentially five years.
The reports here are 30 days, and again, the EFS technically is 30 days for this study.
What were the main endpoints that you studied?
We had a safety endpoint that was a composite rate of major adverse events at 30 days,
and these included device related adverse events, including death, myocardial infarction,
disabling stroke, life threatening bleeding, renal failure, emergency surgery, and the need
for additional procedures due to device failure.
These endpoints were adjudicated according to T-VARC definitions that tricuspid valve academic
research consortium definitions.
We had performance endpoints of the valve that included both technical, procedural, and clinical
success, so we had device technical success, which is the exit from the CAF lab and delivery
and deployment of the valve in the correct position.
We had procedural success, which is, again, freedom from major events up to 30 days.
We had clinical success, which is procedural success without any major adverse events
at 30 days.
We had an echocardiographic endpoint, which was reduction in T-R grade from baseline to
pose procedure.
We used a six-grade scheme, which is now the currently used scheme that included massive
and torrential.
We had other measures, including parapheral elique, inflow gradient, right from particular function
as assessed by TAPSI.
We looked at cardiac output.
We also looked at some functional endpoints, including change in near-card association class,
and the Kansas City Cardiomopathy questionnaire, KCCQ, changes, which were both assessed at
baseline and. 30 days. If you could now walk us through the main results, what sort of patients, the demographic
components, and also the important procedure and points that you just described. So we had 19 patients,
79% of them were female with the mean age of 76 years that were treated at five different
sites. There were a number of other comorbidities that we saw in these patients that are common in
this age and pathology for TR that included diabetes, hypertension, atrial fibrillation,
which was in 74% of patients. 10% of patients had prior cardiac surgery, lung disease that was
moderate or greater than 11% of patients. Most of the patients were in class three or four heart
failure. RV function varied from normal to severely impaired at baseline, and the mean
taxi was 12.8, so certainly it was reduced. And we had nine out of the 19 patients that were
classified as severe RV dysfunction. Again, remembering that this is commonly excluded from
prior valve trials. So all 19 of the patients received the trisol valve, and one valve was used
in all cases. At the end of discharge, all of the patients had a reduction in TR, and 94% showed
an improvement of two or more grades. There was one intra procedural death in which the valve was
being retrieved, which tore one of the large vessels adjacent to the heart or next to the heart
and the patient expired in the operating room. All of the procedures were performed with general
anesthesia and TE guidance. 16 of the patients have completed 30-day follow-up with one procedural
death. There were two patients that withdrew from the study just in good health, but did not want
to participate anymore, unfortunately. So we had 16 patients with clinical follow-up. There were
no patients of these 16 that suffered a mortality after the 30 days, other than the one procedural
death. We had no patients that had major renal failure. There was a temporary acute kidney injury
in one patient. There was no major bleeding, and again, which is really remarkable considering that
these are 32-French devices that are going through the neck. The rate of bleeding in other trials
has been quite significant. So that was lovely. Patients were maintained on a NOAC or DOAC,
but again, we didn't experience any major bleeding, which was wonderful. We had significant
improvements in functional status. We had all patients improved in New York Heart Association class.
We had six-minute walk tests that improved significantly, and we also had the KCCQ scores
that improved quite significantly, again, from almost 20 to 30 percent. In terms of other major
complications, there were no other valvary interventions. Procedural and technical success was 95 percent.
There were no strokes, no myocardial infarctions. Total device time was 50 minutes, and total
fluoroscopy time was 42 minutes. So overall, a relatively rapid procedure considering things.
We had one patient that had third degree block, so one pacemaker out of these 19. So the echocardiography
was also very important, and we saw some important things. We had a baseline gradient that was
1.1, and that increased to 1.9 at 30 days. So typically, when we see prosthetic valves, either surgical
or transcatheter, their gradients are 4 to 5. This valve is quite large. Its inner diameter is
almost the size of a native valve, so over 5 millimeters squared in terms of area, which is twice
the size of many of the other valves out there. So we do see this very low gradient that was
maintained throughout the time period at 30 days, both procedurally and at follow-up. And so that
may help contribute again to some of the preservation of RV function that we think is happening.
With this large valve, you have a very large ability to preserve cardiac output. We saw a numerical
increase in cardiac output. All of the patient's cardiac output improved, although it did not reach
statistical significance. It went from four leaders to five leaders. So a 20% increase in cardiac
output in these patients. We had a very mild reduction in TAPC. Statistically, it didn't change,
but it was numerically, you know, went from 13 to 11. This is in contrast to other commercial
studies for replacement valves in which the TAPC and the RV function declined or deteriorated
significantly. So in this regard, I think we were very confident in saying that we think that
this valve does help us allow preservation of RV function. In terms of leak, there was two patients
with residual leak, tricuspid leak, combined from the middle of the valve as well as the side
of the valve. And everyone else was basically mild or less. So 88% of mild or less leak.
You did explain very nicely about the preservation of RV function being one of the advantages of
this valve in comparison to the experience of other studies with different peculiarness tricuspid
valves. What other outcomes would you say are different with the tri-sol system in comparison with
early experience of TTVRC in the Transcend studies? You know, one of the, one of the things that
are just challenging for us clinically are one are pacemakers. So dealing with pacemakers,
putting it in in the coronary sinus, sometimes you have to go through the valve. Do you do a
a leadless pacemaker? Do you leave a wire across a new fresh valve? I mean, those are always really
challenging things to do and we're worried about these, these leads damaging leaflets. So it's a big
deal for us to be able to say that we have a very low pacemaker rate. And I think that's an important
thing for being able to help preserve the leaflets for as long as possible. The second thing is
the absence of major clinical halt or leaflet thrombosis. We have not seen that in any patient
in any series out of all of the patients that we've done as part of this study or the early study.
This is again also in contrast to the very high rates of subclinical and clinical leaflet thrombosis
that we see in a real-world experience of tricuspid valve replacements that are currently on the
market. They can be up to 12.5% to 30% of patients and patients then have to get transitioned to a very
strong anti-coagulant. Let's say a vitamin K antagonist. That increases bleeding. We've also seen
early failure of these valves when you get home as this clot layers in a right-sided environment
with stasis and lower pressures. The valves don't open as well. The leaflets don't open clot forms
and it becomes very difficult to get rid of that clot. You end up putting patients on very high
levels of these blood thinners and they have bleeding complications and no question will somewhat
will likely impact the durability of the leaflets. I think the way this valve looks on echo and
it's I think it's really important to be able to see that on some sample echoes. You'll see that
they're washing throughout this cycle and systole and diastole and that does allow blood to flow
very freely. Maybe even like what we see in a native tricuspid valve. That's really interesting
and thank you for explaining the design aspects of this valve that facilitates some of its
favorable outcomes. This is of course an ongoing study and thank you for reporting its early
experience in your intervention. What plans for the future in terms of further investigating?
So we have we have a couple of things coming up. When we are going to be starting a pivotal study
in the United States and that will be a comparison of this valve to the evoke valve for patients who
have suitable anatomy. We will also have a registry, a nested registry and this will be patients who
have unsuitable anatomy or the evoke. That can consist of both annular size that is not treated by
the evoke as well as RV function and I think that'll be a very interesting and actually a very
high enrolling study. I think there's been a problem with that in terms of getting the patients
who are the sickest treated and so these vulnerable patients have challenging outcomes. They have
challenging procedural. If we're able to treat these patients effectively independent of anything
else, I think that's a win for patients and that's an important thing for us to be able to provide
that therapy for that group. The main cohort will again be studied. It will be a one-year outcome
with a comparison of again a primary safety endpoint and a performance endpoint that we've seen.
It is a combination of some functional parameters as well as clinical parameters. So safety
as well as change in KCCQ and immortality grown in there as a part of a composite endpoint.
It will be very interesting. I think we have some new additions to the valve that will also
be very important as we start this new trial. The valve is retrievable. That's another important
aspect that's very unique compared to every other valve basically. So up until the very last
release point, you can retrieve the valve. You can reverse everything. You can reposition it.
You can re-grab leaflets until you're happy and you can do that until you get the perfect position.
In addition, we have a range of sizes that will
be available. We have both, again, access from the neck as well as the groin. We have additional
rotational elements that will help get an additional dimension of freedom to manipulate and position
the valve. So I think those are really nice things that we'll have in this next study. At some point,
we will continue the study on into Europe and to, you know, outside the United States. And that'll
be an important growing, growing addition to the clinical trial landscape.
Thank you, Professor George, for discussing the further aspects in terms of investigations
with these valves and the expansion to outside of the United States as well. And thank you for
discussing your paper on this podcast. It's my pleasure. I look forward to seeing the paper
in print. And I thank you for your time and appreciate your questions.
Thank you for listening to Editor's Choice. To read the full article discussed in this
episode, visit eurointervention.org. And if you've enjoyed this podcast, please subscribe to
Editor's Choice for more conversations behind the science published in eurointervention.
Podcast Summary
Key Points:
The tricuspid valve has gained renewed attention, with new devices like the Trisol TTVR system expanding treatment options for severe tricuspid regurgitation.
The Trisol early feasibility study evaluated a second-generation valve with 12 anchors, a large atrial skirt, and bi-leaflet bovine pericardium design, enabling low closure forces and reduced thrombosis risk.
The study included 19 patients with severe symptoms, poor right ventricular function, and comorbidities previously excluded from prior trials, showing high procedural and clinical success rates.
Key outcomes included significant improvement in TR grade (94% improvement of two or more grades), preserved right ventricular function, and a low rate of major adverse events—no deaths, strokes, or MI, and only one pacemaker insertion.
The device demonstrated a low gradient (1.1 to 1.9), increased cardiac output, and reduced TAPSE compared to other valves, suggesting superior hemodynamic performance and RV preservation.
Notably, there was no evidence of leaflet thrombosis or post-procedural valve failure, addressing a major limitation in current tricuspid valve therapies.
The valve offers retrievability, flexible access (neck or groin), and a large size up to 65 mm, allowing treatment of late-presenting and anatomically complex patients.
Future studies will compare Trisol to the Edwards Evolve valve, include patients with unsuitable anatomy, and expand to Europe, aiming to improve access for high-risk and underserved populations.
Summary:
The Trisol TTVR early feasibility study presents promising early results for treating severe tricuspid regurgitation in patients previously excluded from prior therapies. In a single-arm, multicenter trial of 19 patients, the device demonstrated high procedural and clinical success—95% technical success and 100% procedural success—alongside significant improvements in tricuspid regurgitation grade (94% showed ≥2-grade reduction), functional status (improved NYHA class, 6-minute walk test, and KCCQ scores), and right ventricular function. Notably, the study reported no major adverse events such as death, stroke, or myocardial infarction, and only one pacemaker insertion, indicating minimal conduction-related complications.
9), and unique bi-leaflet design with continuous blood washout help preserve right ventricular function, a key advantage over existing valves where RV dysfunction commonly worsens. No leaflet thrombosis was observed, addressing a major clinical concern in current tricuspid replacement therapies. The device is retrievable, allows flexible positioning, and can be delivered via neck or groin access.
Future pivotal trials will compare Trisol to the Edwards Evolve valve and include patients with challenging anatomy or poor right ventricular function. The results suggest Trisol may offer a safer, more effective, and broadly applicable option for severe tricuspid regurgitation, particularly in high-risk populations.
FAQs
Two devices are commercially approved: the Abbott tri-clip edge-to-edge device and the Edwards EVOKE replacement system, both for patients with symptomatic severe tricuspid regurgitation and suitable anatomy at elevated surgical risk.
The trisol TTVR is a new valve with a large opening design, 12 anchors, and a bi-leaflet system made of bovine pericardium. It features low opening/closing forces, significant blood washing, and a reduced risk of leaflet thrombosis compared to other valves.
The study measured a composite rate of major adverse events at 30 days, including death, MI, stroke, and bleeding. Performance endpoints included technical success, procedural success, clinical success, TR grade reduction, and improvements in functional status and cardiac output.
All 19 patients showed a reduction in tricuspid regurgitation grade, with 94% improving by two or more grades. There were no deaths after 30 days except one procedural death. No major bleeding or stroke occurred, and RV function was preserved in most patients.
The valve’s large opening and low gradient (1.1 to 1.9) allow better blood flow and reduce pressure on the right ventricle. This results in improved cardiac output and a numerical reduction in TAPSE, indicating better RV function compared to other valves.
The valve has a very low pacemaker rate (only 1 out of 19 patients), no leaflet thrombosis, and a retrievable design that allows repositioning and re-grabbing of leaflets for optimal placement.
Chat with AI
Loading...
Pro features
Go deeper with this episode
Unlock creator-grade tools that turn any transcript into show notes and subtitle files.